These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 26561833)

  • 1. Questionnaire about the adverse events and side effects following botulinum toxin A treatment in patients with cerebral palsy.
    Blaszczyk I; Foumani NP; Ljungberg C; Wiberg M
    Toxins (Basel); 2015 Nov; 7(11):4645-54. PubMed ID: 26561833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic adverse events after botulinum neurotoxin A injections in children with cerebral palsy.
    Paget SP; Swinney CM; Burton KLO; Bau K; O'Flaherty SJ
    Dev Med Child Neurol; 2018 Nov; 60(11):1172-1177. PubMed ID: 30146721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Botulinum toxin A for nonambulatory children with cerebral palsy: a double blind randomized controlled trial.
    Copeland L; Edwards P; Thorley M; Donaghey S; Gascoigne-Pees L; Kentish M; Cert G; Lindsley J; McLennan K; Sakzewski L; Boyd RN
    J Pediatr; 2014 Jul; 165(1):140-146.e4. PubMed ID: 24630348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High doses of a new botulinum toxin type A (NT-201) in adult patients with severe spasticity following brain injury and cerebral palsy.
    Intiso D; Simone V; Di Rienzo F; Iarossi A; Pazienza L; Santamato A; Maruzzi G; Basciani M
    NeuroRehabilitation; 2014; 34(3):515-22. PubMed ID: 24473245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Severity of cerebral palsy and likelihood of adverse events after botulinum toxin A injections.
    Swinney CM; Bau K; Burton KLO; O'Flaherty SJ; Bear NL; Paget SP
    Dev Med Child Neurol; 2018 May; 60(5):498-504. PubMed ID: 29451702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative evaluation for spasticity of calf muscle after botulinum toxin injection in patients with cerebral palsy: a pilot study.
    Lin YC; Lin IL; Chou TF; Lee HM
    J Neuroeng Rehabil; 2016 Mar; 13():25. PubMed ID: 26969526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety profile of incobotulinum toxin A [Xeomin(®)] in gastrocnemious muscles injections in children with cerebral palsy: Randomized double-blind clinical trial.
    Carraro E; Trevisi E; Martinuzzi A
    Eur J Paediatr Neurol; 2016 Jul; 20(4):532-7. PubMed ID: 27177451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment with Botulinum toxin A in a total population of children with cerebral palsy - a retrospective cohort registry study.
    Franzén M; Hägglund G; Alriksson-Schmidt A
    BMC Musculoskelet Disord; 2017 Dec; 18(1):520. PubMed ID: 29228927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of treatment concepts for the use of botulinum toxin a in children with cerebral palsy.
    Placzek R; Siebold D; Funk JF
    Toxins (Basel); 2010 Sep; 2(9):2258-71. PubMed ID: 22069684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic adverse events following botulinum toxin A therapy in children with cerebral palsy.
    Naidu K; Smith K; Sheedy M; Adair B; Yu X; Graham HK
    Dev Med Child Neurol; 2010 Feb; 52(2):139-44. PubMed ID: 20412252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of Botulinum Toxin Type A for Children With Nonambulatory Cerebral Palsy.
    Edwards P; Sakzewski L; Copeland L; Gascoigne-Pees L; McLennan K; Thorley M; Kentish M; Ware R; Boyd RN
    Pediatrics; 2015 Nov; 136(5):895-904. PubMed ID: 26482662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combining strength training and botulinum neurotoxin intervention in children with cerebral palsy: the impact on muscle morphology and strength.
    Williams SA; Elliott C; Valentine J; Gubbay A; Shipman P; Reid S
    Disabil Rehabil; 2013 Apr; 35(7):596-605. PubMed ID: 22928803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A French observational study of botulinum toxin use in the management of children with cerebral palsy: BOTULOSCOPE.
    Chaléat-Valayer E; Parratte B; Colin C; Denis A; Oudin S; Bérard C; Bernard JC; Bourg V; Deleplanque B; Dulieu I; Evrard P; Filipetti P; Flurin V; Gallien P; Héron-Long B; Hodgkinson I; Husson I; Jaisson-Hot I; Maupas E; Meurin F; Monnier G; Pérennou D; Pialoux B; Quentin V; Moreau MS; Schneider M; Yelnik A; Marque P
    Eur J Paediatr Neurol; 2011 Sep; 15(5):439-48. PubMed ID: 21745754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse effects following botulinum toxin A injections in children with cerebral palsy.
    Sapienza M; Kapoor R; Alberghina F; Maheshwari R; McCracken KL; Canavese F; Johari AN
    J Pediatr Orthop B; 2023 Sep; 32(5):435-451. PubMed ID: 36723611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Efficacy and Side Effects of Oral Baclofen Versus Tizanidine Therapy with Adjuvant Botulinum Toxin Type A in Children With Cerebral Palsy and Spastic Equinus Foot Deformity.
    Dai AI; Aksoy SN; Demiryürek AT
    J Child Neurol; 2016 Feb; 31(2):184-9. PubMed ID: 25999301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and self-reported efficacy of botulinum toxin for adult spasticity in current clinical practice: a prospective observational study.
    Muller F; Cugy E; Ducerf C; Delleci C; Guehl D; Joseph PA; Burbaud P; Dehail P
    Clin Rehabil; 2012 Feb; 26(2):174-9. PubMed ID: 21937525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IncobotulinumtoxinA Efficacy/Safety in Upper-Limb Spasticity in Pediatric Cerebral Palsy: Randomized Controlled Trial.
    Dabrowski E; Chambers HG; Gaebler-Spira D; Banach M; Kaňovský P; Dersch H; Althaus M; Geister TL; Heinen F
    Pediatr Neurol; 2021 Oct; 123():10-20. PubMed ID: 34339951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term Safety and Dosing of OnabotulinumtoxinA: A Prospective, Observational Study.
    Wein T; Jog M; Bhogal M; Dhani S; Miller R; Ismail F; Beauchamp R; Trentin G
    Can J Neurol Sci; 2019 Nov; 46(6):742-752. PubMed ID: 31256770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Upper extremity spasticity in children with cerebral palsy: a randomized, double-blind, placebo-controlled study of the short-term outcomes of treatment with botulinum A toxin.
    Koman LA; Smith BP; Williams R; Richardson R; Naughton M; Griffin L; Evans P
    J Hand Surg Am; 2013 Mar; 38(3):435-46.e1. PubMed ID: 23428186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Letter to the editor: Re: Safety of botulinum toxin type A among children with spasticity secondary to cerebral palsy: a systematic review of randomized clinical trials.
    Dubinsky RM
    Clin Rehabil; 2010 Aug; 24(8):766. PubMed ID: 20702516
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.